BACKGROUND: This study questions the 6-month duration criterion for generalized anxiety disorder (GAD) used in DSM-III-R and DSM-IV. METHOD: In adults from age 20/21 to 40/41 in the prospective Zurich Cohort Study, four groups of generalized anxiety syndromes defined by varying duration (2 weeks, 1 month, 3 months and 6 months) were compared. RESULTS: Applying DSM- III (1979III ( -1999 and DSM-III-R (1986-1999) criteria, there were no significant differences between the four groups in terms of family history of anxiety, work impairment, distress, treatment rates or co-morbidity with major depressive episodes (MDEs), bipolar disorder or suicide attempts. Only social impairment related to the length of episodes. The 6-month criterion of DSM-III-R and DSM-IV GAD would preclude this diagnosis in about half of the subjects treated for generalized anxiety syndromes. CONCLUSIONS: In this epidemiological sample, the 6-month duration criterion for GAD could not be confirmed as clinically meaningful. GAD syndromes of varying duration form a continuum with comparable clinical relevance.
INTRODUCTION
Generalized anxiety disorder (GAD) with a minimum duration of 2 weeks was first operationally defined in the Research Diagnostic Criteria by Spitzer et al. (1978) , in order to separate GAD from panic disorder following Klein's observations (1964) of differential responses to drugs ; comprehensive historical reviews of the conceptual development were published by Blazer et al. (1991) and Rickels & Rynn (2001 a) . From DSM-III (1980) through DSM- III-R (1987) to DSM-IV (1993) , the definition of GAD underwent considerable changes in the composition and number of required symptoms and their minimum duration (from 1 month to 6 months). This extension in length was mainly a consequence of concerns about the co-morbidity of GAD with major depression (Breier et al. 1985 ; Breslau, 1985 ; Breslau & Davis, 1985 ; Brown et al. 1995 Brown et al. , 1998 Starcevic, 1995 ; Sartorius et al. 1996) . However, it is now well established that GAD and major depression are often independent disorders and their co-morbidity is not greater than that of other disorders, as shown by data from the National Comorbidity Survey (Kessler et al. 1999 ; Kessler, 2000) and discussed in the comprehensive review of Kessler et al. (2001) .
Our longitudinal Zurich Cohort Study, with six interviews from 1979 to 1999, had to cope with all the DSM diagnostic changes. Assessing anxiety not tailored to the changing diagnostic concepts, we found, comparable to the depression spectrum (Angst & Gamma, 2002 a, b) , a wide spectrum of anxiety, from recurrent brief anxiety states of a few days' duration to longerlasting episodes of weeks and months (Angst & Wicki, 1992) . Well-founded serious doubt about the value of the duration criterion of GAD were expressed by Bienvenu et al. (1998) on the basis of the Baltimore Epidemiologic Catchment Area (ECA) Program ; their data demonstrated that the GAD syndrome of six symptoms was clinically coherent but that there were no differences between 1-month and 6-month GAD in terms of co-morbidity and demographic correlates. A recent paper on the National Comorbidity Survey Replication in the USA (Kessler et al. 2005 ) also found that maximum episode duration (1-2, 3-5, 6-11, o12 months) was unrelated to most measures of impairment, co-morbidity and sociodemographics. These results were in line with those of an analysis by Maier et al. (2000) of the ICD-10 criteria for GAD in the large World Health Organization (WHO) study on 'Psychological Problems in Primary Care'. Twin research showed that the fit of models taking environmental and genetic factors into account did not differ whether GAD was defined using a 1-month or a 6-month minimum duration (Kendler et al. 1992) . Finally, Rickels & Rynn (2001 a) stressed in their extensive historical review that it is not duration of illness or excessive worry focus (Borkovec, 1994 ; Borkovec et al. 1991 ; Brown, 1997) but the severity of anxiety symptoms that is most relevant for the diagnosis and treatment of GAD.
Assuming, in analogy to depression, the existence of a spectrum of anxiety (Rickels & Schweizer, 1997) , from brief spells lasting a few days to chronic severe manifestations, the purpose of this paper was to compare generalized anxiety syndromes, defined by the symptom criteria of DSM-III, DSM-III-R and DSM-IV and varying duration (2 weeks, 1 month, 3 months and 6 months), and to present prevalence, clinical characteristics and clinical validity of these four subgroups.
METHOD Sample
The original Zurich study (A Prospective Epidemiological Study of Depressive, Neurotic and Psychosomatic Syndromes) identified a representative sample of young adults in the Zurich canton (population then 1 . 1 million) by randomly selecting from all 19-year-old men as they presented themselves for compulsory military service (born 1959) and all women who were 20 years of age (born 1958) . Details of sampling procedures and refusal rates are presented in the original publication (Angst et al. 1984) .
The Zurich study involved a sample of 4547 subjects (2201 males, 2346 females) representative of the canton of Zurich in Switzerland, who were screened in 1978 with the Symptom Checklist 90-R (SCL-90-R ; Derogatis, 1977) , a comprehensive self-report questionnaire of 90 questions that has been validated as a screening instrument and covers a broad range of psychiatric symptoms.
To increase the probability of the development of psychiatric syndromes, a stratified subsample of 591 subjects (292 males, 299 females) was selected for interview, with two-thirds consisting of high scorers (above the 85th percentile) on the Global Severity Index of the SCL-90-R, and one-third consisting of a random sample of those with lower scores. This stratified sample represents, weighted, 2600 persons of the same age from the general population. The screening took place in 1978, when the male participants were 19 and the females 20 years of age. Six interview waves were conducted across 20 years from 1979 to 1999. There were no major differences in sociodemographics between males and females.
The Structured Psychopathological Interview and Rating of Social Consequences of Psychic Disturbances for Epidemiology (SPIKE) was administered (Angst et al. 1984) . The SPIKE assesses a series of somatic complaints, including insomnia, headache, gastrointestinal, cardiovascular, respiratory, perimenstrual and sexual syndromes. It also assesses depression, hypomania, anxiety, phobias, obsessive-compulsive symptoms, eating disorders, post-traumatic stress disorder, substance abuse and suicidal phenomena. Validity and reliability tests were performed with particular reference to depression and anxiety. All subjects were approached at each interview, irrespective of cooperation with previous interviews, unless they clearly specified that they did want not to be contacted. The interviewers were mostly graduated clinical psychologists and some psychiatrists with special interview training. The inter-rater reliability of the SPIKE was found to be high with k values of 0 . 89 and 0 . 91 for the symptoms of depression and anxiety (GAD) and 0 . 90 for the corresponding syndromal diagnoses. Further methodological details, including studies on validity, have been published by Angst et al. (2005) .
Across 20 years, 62 . 1% of the original sample continued to participate in the study, and the following proportions participated in specific numbers of interviews : 47 % in all six interviews ; 63 % in five; 74% in four ; 82 % in three ; and 91 . 4% in at least two interviews. Those who dropped out did not differ significantly from those who stayed in follow-up interviews and took part in the 1999 interview regarding stratified sampling and most demographic characteristics (Eich et al. 2003) .
The Zurich study provides an unusual healthcare context. There are very few external constraints concerning the utilization of health-care institutions. All inhabitants have insurance coverage, with effectively free care (except with psychotherapists not working under the supervision of a physician or a psychiatrist). There are no waiting lists, and both primary and secondary care (e.g. psychotherapists and psychiatrists) can be accessed directly ; drug prescribing is not centrally dictated or limited.
Diagnoses and clinical characteristics DSM-III GAD could be diagnosed for all six interviews , DSM-III-R GAD for the last four interviews (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) and strict DSM-IV criteria only for the last interview in 1999, due to changes in criteria developed and published by the American Psychiatric Association. In the 1993 interview, DSM-IV criterion B for GAD (difficult to control the worry) was not applicable yet, but criteria A and C were. We therefore also tentatively diagnosed a DSM-IV syndrome for this year. The duration of GAD syndromes was subclassified into 2 weeks, 1 month, 3 months and 6 months in order to investigate the consequences of sharpening the time criterion. A 2-week duration was chosen by analogy with major depression. Briefer highly recurrent episodes of DSM-III GAD syndromes meeting the criterion of recurrent brief anxiety (RBA ; Angst & Wicki, 1992) were not included in the GAD concept, because they were found to be strongly associated with repeated panic attacks. The symptoms were collected by the interviewers over the past 12 months and by the SCL-90-R (Derogatis, 1983) over the past 2 weeks. Only SCL-90-R symptoms with an intensity over 2 (quite a bit or extremely) were taken into account. Summarizing all six interviews, a hierarchical classification of GAD syndromes was applied : 6 months>3 months>1 month>2 weeks.
Other psychiatric diagnoses were made according to the most recent applicable DSM version. Diagnoses were made by algorithms on the basis of DSM-III criteria (panic disorder), DSM-III-R criteria [major depressive disorder (MDD), phobias, obsessive-compulsive disorder (OCD)] and DSM-IV criteria (post-traumatic stress disorder and substance abuse/dependence). Bipolar-II disorder was defined by broad criteria [major depressive episodes (MDEs) plus two of seven symptoms of hypomania with a minimum duration of 1 day]. Exclusion criteria were not applied, in order to investigate the associations between diagnostic categories. Adjustment disorders were not diagnosed in our interview.
Age of onset was evaluated retrospectively after having assessed the whole syndrome, and was defined as the first manifestation of the characteristic symptoms ; these did not have to qualify for the diagnosis.
Across all interviews, work and social impairment as a consequence of anxiety were recorded as present or absent, and distress was estimated by an analogue scale (0-100). Treatment was defined as professional treatment by an M.D. or a psychologist and was assessed separately for each syndrome (e.g. depression, anxiety, panic, etc.) for the past 12 months, for every year between interviews and lifetime. Family history was assessed using a list of all relatives, asking whether they manifested a certain syndrome, illustrated by stem questions and additional symptoms but without the application of formal diagnostic criteria ; relatives' treatment was also assessed.
Statistics

Most analyses involved x
2 tests applied to frequencies and Kruskal-Wallis tests applied to continuous data. In addition, a classification tree analysis was conducted to distinguish treated from untreated cases, using a minimal number of sequential binary decisions derived from a variety of classifying or predictor variables. These variables comprised the number of DSM-III-R or DSM-IV anxiety symptoms, symptom duration, symptom frequency, sex and risk group used for sample stratification. The tree analysis was used as one more way to assess the importance of the duration criterion with regard to the clinical severity of anxiety syndromes. STATA 8.2 (StataCorp., College Station, TX, USA) and STATISTICA 6.0 (StatSoft Inc., Tulsa, OK, USA) were used for data analysis. Fig. 1 presents the overlap of 1-month GAD syndromes for the last four interviews (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , defined by DSM-III, DSM-III-R and modified DSM-IV criteria (without criterion B). It demonstrates very strong associations among the three concepts. DSM-III (105 cases) was the broadest concept, embracing 61of 62 DSM-IV cases and 85 of 97 DSM-III-R cases. The results show that DSM-IV syndromal criteria for GAD are more restrictive than DSM-III and DSM-III-R criteria. Because DSM-III GAD criteria were applicable to all six interviews , we present a more extensive analysis of them compared to DSM-III-R criteria, which were applicable to interview waves 4-6 (1986-1999) . Tentatively, we analysed DSM-IV GAD in the same way (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , although criterion B (worries) was not assessed in all interviews.
RESULTS
Overlap of GAD concepts based on four interviews (1986-1999)
Severity of GAD subgroups by duration and diagnostic concept (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) In Table 1 , subjects with GAD, classified by the three diagnostic versions of DSM and duration, are presented with their total symptom scores as measures of severity. It is impressive that neither the temporal subgroups nor the diagnostic concepts have great impact on the severity scores ; from a clinical point of view the differences are minor. It is notable that 2-week GAD was overall as severe as 3-month GAD, while the values of 1-month GAD tended to be lower and those of 6-month GAD slightly higher. Table 2 compares the four DSM-III GAD syndromes by minimum duration : 2 weeks, 1, 3 and 6 months. The four categories are hierarchical and mutually exclusive. The cumulative prevalence rates varied between 2 . 5 % (2 weeks) and 5 . 9% (1 month). The prevalence rate for all DSM-III generalized anxiety syndromes with a minimum duration of 2 weeks or more was 16 . 5% ; only 3 . 2% of them lasted 6 months or longer. Most potential validators did not distinguish between the four groups: sociodemographic variables, family history of anxiety, work impairment, age of onset, distress, lifetime treatment rates for anxiety and depression and co-morbidity. The co-morbidity data demonstrate that 2-week GAD was not more associated with MDD or bipolar-II disorder than 6-month GAD ; in both cases the trend was towards the opposite direction. Generally 6-month GAD tended to have higher comorbidity than 2-week GAD. Only social impairment was positively related to the duration of DSM-III GAD (Table 2) . A family history of depression was exceptionally frequent for 3-month GAD. It is remarkable that the treatment rates for depression were especially high in the categories of 3-month and 6-month GAD and in general comparable to the treatment rates for anxiety. With the exception of sociodemographic variables, the four GAD groups differed significantly from the controls without anxiety symptoms (n=203).
Sociodemographic and clinical characteristics of DSM-III GAD syndromes varying by duration
Clinical characteristics of DSM-III-R GAD syndromes varying by duration
Very similar results were obtained on applying the DSM-III-R definition of GAD to the four groups varying by duration. We found that 4 . 5% of the population were identified as having DSM-III-R GAD, 7 . 7 % had 1-month GAD, 6 . 2% 3-month GAD and 2 % 2-week GAD. Table 3 gives a summary of some important validators. Among the GAD groups, there were no significant differences, whereas the GAD groups differed significantly from the controls, except for the sociodemographic variables. The co-morbidity of GAD with MDE was independent of the duration of the episodes ( p=0 . 99). Again, the treatment rates for depression were especially high in the categories of 3-month and 6-month GAD and comparable to the treatment rates for anxiety. An analogous table for approximated DSM-IV GAD syndromes is not presented because there was almost complete overlap with DSM-III R GAD cases, and because criterion B of DSM-IV GAD could not be assessed except in the 1999 interview.
Undiagnosed treated GAD cases
It is of great practical interest to determine the number of patients with a GAD syndrome of at least 2 weeks' duration, who were treated professionally by MDs or psychologists for generalized anxiety during the interview years but did not meet DSM criteria for GAD. The DSM-III concept missed only eight of 51 treated cases (15 %) across all six interviews because the duration of symptoms in these cases was less than 1 month. As a consequence of the 6-month criterion, the DSM-III-R concept (applicable in the last four interviews) missed 23 of 40 treated cases (57 . 5 %), and the DSM-IV concept (without Table 1 . Generalized anxiety disorder (GAD) DSM-III, DSM-III R, approx. DSM-IV (1986 -1999 and severity by sums of criterial symptoms criterion B and applicable to the last two interviews) missed 13 of 27 treated cases (49 %). In the last interview, where the precise DSM-IV diagnosis was possible, five of 10 treated cases (50 %) were missed ; these all had a duration of at least 1 month. Table 4 shows that treatment rates steadily increased with increasing numbers of DSM-III-R or DSM-IV symptoms. Treatment also increased when symptoms became more frequent. Duration of anxious episodes, however, had no impact on treatment rates.
The tree analysis for treatment from 1986 to 1999 showed that the number of DSM symptoms alone was sufficient for optimal classification of treated versus non-treated cases. A cut-off of 15 . 1 DSM-III-R symptoms or 5 . 5 DSM-IV symptoms yielded optimal classification ; this suggests that treated participants were quite symptomatic, on average. Duration of episodes turned out to be the least important predictor of treatment.
DISCUSSION
In this study a diagnosis of a generalized anxiety syndrome was made on the basis of the symptoms only, independent of duration, in order to test the consequences of a minimum duration of 6 months as required in DSM-III-R, DSM-IV and ICD-10. We found a large number of cases with a 1-month and 3-month duration and fewer with a 2-week duration. Half of all patients treated for a generalized anxiety syndrome defined by DSM-III symptom criteria would not be identified as having GAD using DSM-III-R or DSM-IV criteria, mainly as a consequence of the 6-month criterion. This finding is compatible with the doubts about the utility of the DSM-III-R and DSM-IV diagnostic constructs expressed by Rickels and Rynn (2001 a) . Generalized anxiety syndromes of shorter duration (2 weeks, 1 month, 3 months), defined by DSM-III and other DSM-III-R criteria, did not differ significantly in a number of sociodemographic and clinically relevant variables from syndromes with a 6-month duration ; for instance, in severity, family history of anxiety, phobias and depression, age of onset, work impairment, distress or treatment rates. Symptom duration without regard to diagnostic criteria also showed no impact on treatment rates. Furthermore, for optimal classification of treatment cases in a tree analysis, symptom duration was the least important classifier and not needed for optimal classification. Only social impairment increased with duration of the DSM-III generalized anxiety syndrome, but not if DSM-III-R criteria were applied.
Co-morbidity was also comparable across the four groups; all psychiatric diagnoses assessed were equally associated with GAD syndromes of varying length, including MDEs. Thus, our study confirms the results of Bienvenu et al. (1998) and Kessler et al. (2005) as well as our earlier analysis (Angst, 1999) .
Comparisons of GAD syndromes of 1-month duration showed a great overlap among the subjects meeting DSM-III, DSM-III-R and modified DSM-IV definitions; this demonstrates the stability of the GAD concept. Two-week GAD cases (as originally defined by the Research Diagnostic Criteria) compared to 1-month cases showed equal or even slightly higher distress, impairment and treatment rates. The severity of anxiety is not dependent on duration, as illustrated by panic attacks and recurrent brief anxiety of a few days' duration. Further studies will have to clarify the validity of the 2-week definition of GAD in analogy to major depression.
A problem not dealt with in this paper is the difficulty of separating GAD syndromes from depression ; half of the cases met criteria for MDEs but this association was independent of the minimum duration of GAD syndromes. In another paper we show prospectively the high stability of mixed cases of anxiety and depression (Merikangas et al. 2003) .
We found a relatively high cumulative prevalence of GAD syndromes lasting 2 or more weeks (16 . 5 %). Our methods probably had relatively high ' sensitivity ' in capturing these syndromes because of repeated assessments, which could minimize subjects' tendencies to forget episodes.
In conclusion, the data do not support the restriction of the GAD construct to a minimum duration of 6 months. Short and long episodes form a continuum. The restricted definition of 6 months' duration failed to identify 50% of subjects treated professionally for generalized anxiety syndromes, which is worrying if 'the ultimate utility of diagnostic distinctions is to guide treatment decisions ' (Kessler & Wittchen, 2002) . Shorter GAD syndromes did not differ in onset and course from the 6-month cases.
symptoms (autonomic anxiety symptoms were deleted from the list) and additional specifications regarding the nature of worry. We note that changes from DSM-III-R to DSM-IV are not without controversy. For example, although patients with GAD in psychiatric clinics may not frequently or reliably report autonomic anxiety symptoms (Marten et al. 1993) , patients with GAD in primary care settings often do present with these physical symptoms (Rickels & Rynn, 2001 b) . The DSM-IV focus on excessive worry, and the nature of that worry, may also be of limited clinical utility, especially in primary care settings (Olfson et al. 1996 ; Rickels & Rynn, 2001 b) . Thus, the current diagnostic conception of GAD appears to be an imperfect 'moving target'. Nevertheless, our results are fairly consistent across GAD definitions.
The sample size in the current study was relatively small (although enriched by risk cases). This was especially true for DSM-IV cases, whereas the numbers of DSM-III and DSM-III-R cases are more conclusive. Another limitation is the attrition rate of 37 . 9 %, discussed in more detail elsewhere (Eich et al. 2003) .
